Checkpoint Therapeutics (CKPT) Q2 2024 earnings summary

Executive summary

• The company is a clinical-stage oncology firm focused on immunotherapy and targeted treatments, with lead candidate cosibelimab under FDA review after a July 2024 BLA resubmission addressing prior manufacturing issues; FDA set a PDUFA date of December 28, 2024.

• No product sales have been generated; the company has an accumulated deficit of $331.9 million as of June 30, 2024.

• Cash and cash equivalents were $5.0 million at June 30, 2024, projected to fund operations only into Q4 2024, raising substantial doubt about the ability to continue as a going concern without new financing.

• Recent financing includes a $14.0 million offering in January 2024 and $12.0 million in July 2024 to support operations and product development.

• Entered a collaboration to explore cosibelimab with GC Cell's Immuncell-LC therapy.

Financial highlights

• Revenue for Q2 2024 was $41,000, primarily from patent fees.

• Net loss for Q2 2024 was $6.7 million ($0.18 per share), improved from $16.5 million ($1.05 per share) in Q2 2023.

• R&D expenses decreased to $4.5 million in Q2 2024 from $13.9 million in Q2 2023.

• G&A expenses were $2.2 million in Q2 2024, slightly down from $2.3 million in Q2 2023.

• Net cash used in operating activities for the first half of 2024 was $12.7 million, down from $26.0 million in the prior year.

Outlook and guidance

• Expects R&D and G&A expenses to remain consistent for the rest of 2024.

• Cash runway is expected to last into Q4 2024, with additional funding required to continue operations and advance product candidates.

• The FDA review of cosibelimab is ongoing, with a PDUFA goal date of December 28, 2024.

• Plans to address all deficiencies cited in the FDA's December 2023 CRL through the BLA resubmission.